Biohaven Ltd
BHVN13.935USD
-0.135-0.96%
Close 09/12, 16:00（ET）Quotes delayed by 15 min
1.47BMarket Cap
LossP/E TTM
More Details of Biohaven Ltd Company
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; Transient Receptor Potential Melastatin 3 (TRPM3) antagonism for migraine and neuropathic pain; Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; and antibody recruiting, bispecific molecules and antibody drug conjugates (ADCs) for cancer. The Troriluzole is a new chemical entity (NCE) and tripeptide prodrug of the active metabolite, riluzole.
Company Info
Ticker SymbolBHVN
Company nameBiohaven Ltd
IPO dateSep 23, 2022
CEODr. Vlad Coric, M.D.
Number of employees256
Security typeOrdinary Share
Fiscal year-endSep 23
Address215 Church Street
CityNEW HAVEN
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code06510
Phone12034040410
Websitehttps://www.biohaven.com/
Ticker SymbolBHVN
IPO dateSep 23, 2022
CEODr. Vlad Coric, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
1.62M
--
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
193.45K
+0.39%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
34.80K
+757.19%
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Director
Independent Director
25.66K
--
Mr. Kishan (Kishen) Mehta
Mr. Kishan (Kishen) Mehta
Director
Director
22.66K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Lead Independent Director
Lead Independent Director
15.18K
--
Mr. Robert J. Hugin
Mr. Robert J. Hugin
Independent Director
Independent Director
12.96K
--
Dr. Irina Antonijevic, M.D., Ph.D.
Dr. Irina Antonijevic, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. John W. Childs
Mr. John W. Childs
Independent Director
Independent Director
--
--
Dr. Vlad Coric, M.D.
Dr. Vlad Coric, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
1.62M
--
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
193.45K
+0.39%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
34.80K
+757.19%
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Director
Independent Director
25.66K
--
Mr. Kishan (Kishen) Mehta
Mr. Kishan (Kishen) Mehta
Director
Director
22.66K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Lead Independent Director
Lead Independent Director
15.18K
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.72%
1919 Investment Counsel, LLC
6.23%
Childs John W
6.15%
BlackRock Institutional Trust Company, N.A.
6.08%
Suvretta Capital Management, LLC
5.31%
Other
67.49%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.72%
1919 Investment Counsel, LLC
6.23%
Childs John W
6.15%
BlackRock Institutional Trust Company, N.A.
6.08%
Suvretta Capital Management, LLC
5.31%
Other
67.49%
Shareholder Types
Shareholders
Proportion
Investment Advisor
34.60%
Investment Advisor/Hedge Fund
25.54%
Hedge Fund
16.34%
Individual Investor
11.13%
Research Firm
3.52%
Venture Capital
1.11%
Sovereign Wealth Fund
0.85%
Corporation
0.48%
Pension Fund
0.47%
Other
5.96%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
561
102.09M
99.98%
-11.50M
2025Q1
573
104.91M
102.74%
-8.33M
2024Q4
560
105.43M
103.87%
-2.30M
2024Q3
544
99.41M
101.90%
-4.10M
2024Q2
514
95.57M
103.25%
+3.60M
2024Q1
494
86.58M
104.39%
-3.45M
2023Q4
444
83.44M
104.38%
+4.72M
2023Q3
398
73.50M
107.61%
-2.29M
2023Q2
372
72.49M
106.13%
-7.40M
2023Q1
331
78.42M
114.97%
+3.79M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
8.40M
8.23%
+4.76K
+0.06%
Mar 31, 2025
1919 Investment Counsel, LLC
6.59M
6.46%
+34.44K
+0.53%
Mar 31, 2025
Childs John W
6.51M
6.38%
+351.58K
+5.71%
Mar 10, 2025
BlackRock Institutional Trust Company, N.A.
6.32M
6.19%
-61.68K
-0.97%
Mar 31, 2025
Suvretta Capital Management, LLC
5.62M
5.5%
--
--
Mar 31, 2025
Janus Henderson Investors
6.44M
6.3%
-544.20K
-7.79%
Mar 31, 2025
State Street Global Advisors (US)
3.42M
3.35%
-90.13K
-2.57%
Mar 31, 2025
Coric (Vladimir)
3.18M
3.11%
+26.57K
+0.84%
Mar 10, 2025
T. Rowe Price Associates, Inc.
2.74M
2.69%
-594.84K
-17.82%
Mar 31, 2025
Bellevue Asset Management AG
2.04M
2%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
3.16%
Roundhill GLP-1 & Weight Loss ETF
1.85%
Global X Guru Index ETF
1.14%
Virtus LifeSci Biotech Clinical Trials ETF
0.81%
F/m Emerald Life Sciences Innovation ETF
0.61%
Inspire Small/Mid Cap ESG ETF
0.22%
JPMorgan Fundamental Data Science Small Core ETF
0.19%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.09%
BNY Mellon US Small Cap Core Equity ETF
0.07%
Strive Small-Cap ETF
0.05%
View more
iShares Neuroscience and Healthcare ETF
Proportion3.16%
Roundhill GLP-1 & Weight Loss ETF
Proportion1.85%
Global X Guru Index ETF
Proportion1.14%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.81%
F/m Emerald Life Sciences Innovation ETF
Proportion0.61%
Inspire Small/Mid Cap ESG ETF
Proportion0.22%
JPMorgan Fundamental Data Science Small Core ETF
Proportion0.19%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proportion0.09%
BNY Mellon US Small Cap Core Equity ETF
Proportion0.07%
Strive Small-Cap ETF
Proportion0.05%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
